文献速递甲状腺疾病

甲状腺髓样癌蛋白质组学分析确定CAPN1是NF1和RET驱动生长的关键调节因子

Proteomic Profiling of Medullary Thyroid Cancer Identifies CAPN1 as a Key Regulator of NF1 and RET Fueled Growth.
PubMed 文献 · Thyroid · 2025-01-27

该研究对正常C细胞、MTC细胞、MEN2A癌前样本及MTC肿瘤进行蛋白质组学分析,发现CAPN1在MTC样本中广泛上调。敲低或抑制CAPN1可显著减少MTC细胞生长、集落形成和体内异种移植瘤生长,CAPN1抑制剂与凡德他尼或塞尔帕替尼联用可最大化凋亡。

要点

  • CAPN1在甲状腺髓样癌样本中广泛上调。
  • 敲低或抑制CAPN1可显著减少MTC细胞生长、集落形成和体内异种移植瘤生长。
  • CAPN1抑制剂与凡德他尼或塞尔帕替尼联用可最大化凋亡。

核心结论

  • 数据提示CAPN1水平升高通过降低NF1水平支持RET和RAS驱动的生长。
  • CAPN1抑制剂与凡德他尼或塞尔帕替尼联合在MTC细胞中显示最大疗效。

研究设计与样本

  • 对正常C细胞、MTC细胞、MEN2A患者癌前样本和MTC肿瘤进行蛋白质组学分析。
  • 使用短发夹RNA介导的CAPN1敲低或CAPN1抑制剂进行功能实验。
  • 在体外评估CAPN1抑制剂与凡德他尼和塞尔帕替尼的联合效应。

主要发现

  • CAPN1在MTC样本中广泛上调。
  • 短发夹RNA介导的CAPN1敲低或CAPN1抑制剂显著减少MTC细胞生长、集落形成和体内异种移植瘤生长。
  • CAPN1抑制剂在体外与凡德他尼和塞尔帕替尼协同,最大化凋亡。
  • 机制实验提示CAPN1抑制神经纤维瘤蛋白(由NF1编码),CAPN1抑制剂稳定NF1蛋白水平并减少下游RAS/RET对AKT和ERK的激活。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Background: Medullary thyroid cancer (MTC) is a frequently metastatic tumor of the thyroid that develops from the malignant transformation of C-cells. These tumors most commonly have activating mutations within the RET or RAS proto-oncogenes. Germline mutations within RET result in C-cell hyperplasia, and cause the MTC pre-disposition disorder, multiple endocrine neoplasia, type 2A (MEN2A). Single-agent therapies for MTC, including vandetanib (VAN) and cabozantinib for all MTCs and selpercatinib (SEL) for RET-mutated MTC, lead to partial responses but are not curative. Methods: To identify new therapeutic targets for MTC, we conducted proteomic profiling of normal C-cells, MTC cells, pre-malignant MEN2A patient samples, and MTC tumors. Results: From this analysis, we identified CAPN1, a member of the CALPAIN (CAPN) family endopeptidases, as widely upregulated in MTC samples. We found that short hairpin RNA-mediated depletion of CAPN1 or inhibitors of CAPN1 significantly reduced MTC cell growth, colony formation, and xenograft tumor growth in vivo. In addition, we show that CAPN1 inhibitors synergize with VAN and SEL in vitro, maximizing apoptosis. Mechanistic experiments implicate CAPN1 in inhibiting neurofibromin, encoded by NF1, and CAPN1 inhibitors stabilize NF1 protein levels and diminish downstream RAS/RET activation of AKT and ERK. Conclusions: Our data suggest that increased CAPN1 levels support RET and RAS-fueled growth by reducing NF1 levels. We find that combinatorial therapies between CAPN1 inhibitors and VAN or SEL show maximal efficacy in MTC cells.

来源:Thyroid,查看原文。版权归原作者所有。

引用

  1. Khan E, Hylton H, Rajan N, et al. Proteomic Profiling of Medullary Thyroid Cancer Identifies CAPN1 as a Key Regulator of NF1 and RET Fueled Growth. Thyroid. 2025. PMID: 39868924. doi:10.1089/thy.2024.0102

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。